Evaluation of a self-inactivating lentiviral vector expressing simian immunodeficiency virus Gag for induction of specific immune responses in vitro and in vivo

被引:30
作者
Buffa, Viviana
Negri, Donatella R. M.
Leone, Pasqualina
Borghi, Martina
Bona, Roberta
Michelini, Zuleika
Compagnoni, Daniela
Sgadari, Cecilia
Ensoli, Barbara
Cara, Andrea
机构
[1] Ist Super Sanita, Dept Drug Res & Evaluat, I-00161 Rome, Italy
[2] Ist Super Sanita, Natl AIDS Ctr, I-00161 Rome, Italy
[3] Ist Super Sanita, Dept Infect Parasit & Immune Mediated Dis, I-00161 Rome, Italy
关键词
D O I
10.1089/vim.2006.19.690
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Humoral and cellular immune responses have been shown to play a fundamental role in controlling simian and/or simian-human immunodeficiency virus (SIV-SHIV) replication in infected macaques. Therefore, the appropriate induction of both compartments of the immune system should be elicited after immunization. In this context, viral vectors have been proven effective in inducing both humoral and cellular immune responses during immunization protocols after direct injection in vivo. Among them, recombinant self-inactivating lentiviral vectors represent a useful strategy for vaccine development because they efficiently transduce and express foreign genes into a wide variety of mammalian cells. Here we report on the development and evaluation of a self-inactivating HIV-based lentiviral vector expressing a codon-optimized SIV Gag sequence (TY2-SIVGagDX), which when used to transduce dendritic cells mediated in vitro expansion of Gag-specific T cells derived from an SHIV-infected cynomolgus monkey, as measured by interferon (IFN)-gamma enzyme-linked immunospot (ELISPOT) and Cr-51 release standard assays. To evaluate the ability to elicit specific immune responses in vivo, TY2-SIVGagDX was also employed in a vaccination protocol after a single intramuscular injection in BALB/c mice. Results indicated that the vector was able to efficiently induce both cellular and humoral responses, as measured by IFN-gamma, ELISPOT assay and antibody production. These data further confirm that lentiviral vectors encoding viral genes represent an advantageous delivery system for vaccine development.
引用
收藏
页码:690 / 701
页数:12
相关论文
共 60 条
[1]   Enhancement of antitumor immunity against B16 melanoma tumor using genetically modified dendritic cells to produce cytokines [J].
Akiyama, Y ;
Watanabe, M ;
Maruyama, K ;
Ruscetti, FW ;
Wiltrout, RH ;
Yamaguchi, K .
GENE THERAPY, 2000, 7 (24) :2113-2121
[2]   Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine [J].
Amara, RR ;
Villinger, F ;
Altman, JD ;
Lydy, SL ;
O'Neil, SP ;
Staprans, SI ;
Montefiori, DC ;
Xu, Y ;
Herndon, JG ;
Wyatt, LS ;
Candido, MA ;
Kozyr, NL ;
Earl, PL ;
Smith, JM ;
Ma, HL ;
Grimm, BD ;
Hulsey, ML ;
Miller, J ;
McClure, HM ;
McNicholl, JM ;
Moss, B ;
Robinson, HL .
SCIENCE, 2001, 292 (5514) :69-74
[3]  
Anson Donald S, 2004, Genet Vaccines Ther, V2, P9, DOI 10.1186/1479-0556-2-9
[4]   Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques [J].
Baba, TW ;
Liska, V ;
Khimani, AH ;
Ray, NB ;
Dailey, PJ ;
Penninck, D ;
Bronson, R ;
Greene, MF ;
McClure, HM ;
Martin, LN ;
Ruprecht, RM .
NATURE MEDICINE, 1999, 5 (02) :194-203
[5]   Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination [J].
Barouch, DH ;
Santra, S ;
Schmitz, JE ;
Kuroda, MJ ;
Fu, TM ;
Wagner, W ;
Bilska, M ;
Craiu, A ;
Zheng, XX ;
Krivulka, GR ;
Beaudry, K ;
Lifton, MA ;
Nickerson, CE ;
Trigona, WL ;
Punt, K ;
Freed, DC ;
Guan, LM ;
Dubey, S ;
Casimiro, D ;
Simon, A ;
Davies, ME ;
Chastain, M ;
Strom, TB ;
Gelman, RS ;
Montefiori, DC ;
Lewis, MG ;
Emini, EA ;
Shiver, JW ;
Letvin, NL .
SCIENCE, 2000, 290 (5491) :486-492
[6]   Restriction of lentivirus in monkeys [J].
Besnier, C ;
Takeuchi, Y ;
Towers, G .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (18) :11920-11925
[7]   Lentivirally transduced dendritic cells as a tool for cancer immunotherapy [J].
Breckpot, K ;
Dullaers, M ;
Bonehill, A ;
Van Meirvenne, S ;
Heirman, C ;
De Greef, C ;
van der Bruggen, P ;
Thielemans, K .
JOURNAL OF GENE MEDICINE, 2003, 5 (08) :654-667
[8]   A single administration of lentiviral vectors expressing either full-length human immunodeficiency virus 1 (HIV-1)HXB2 Rev/Env or codon-optimized HIV-1JR-FL gp120 generates durable immune responses in mice [J].
Buffa, Viviana ;
Negri, Donatella R. M. ;
Leone, Pasqualina ;
Bona, Roberta ;
Borghi, Martina ;
Bacigalupo, Ilaria ;
Carlei, Davide ;
Sgadari, Cecilia ;
Ensoli, Barbara ;
Cara, Andrea .
JOURNAL OF GENERAL VIROLOGY, 2006, 87 :1625-1634
[9]   Vaccine-induced immunity in baboons by using DNA and replication-incompetent adenovirus type 5 vectors expressing a human immunodeficiency virus type 1 gag gene [J].
Casimiro, DR ;
Tang, AM ;
Chen, L ;
Fu, TM ;
Evans, RK ;
Davies, ME ;
Freed, DC ;
Hurni, W ;
Aste-Amezaga, JM ;
Guan, LM ;
Long, R ;
Huang, LY ;
Harris, V ;
Nawrocki, DK ;
Mach, H ;
Troutman, RD ;
Isopi, LA ;
Murthy, KK ;
Rice, K ;
Wilson, KA ;
Volkin, DB ;
Emini, EA ;
Shiver, JW .
JOURNAL OF VIROLOGY, 2003, 77 (13) :7663-7668
[10]   Efficacy and safety analyses of a recombinant human immunodeficiency virus type 1 derived vector system [J].
Chang, LJ ;
Urlacher, V ;
Iwakuma, T ;
Cui, Y ;
Zucali, J .
GENE THERAPY, 1999, 6 (05) :715-728